Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
ByMarvin Nguyen,Ruchit Shah,Anagha Gogate,Deepak Adhikari,Lisa Herms,Heather Neuhalfen,Aaron Peevyhouse,Scott Cole,Sibel Blau,Mark Walker T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.
Lung cancer is the leading cause of cancer deaths in the USA with an estimated 131,880 deaths in 2021 [1]. Approximately 84% of patients with lung cancer have non-small cell lung cancer (NSCLC) [2], with the majority of cases diagnosed being locally advanced, inoperable or metastatic [1].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
